DocTrials joins Aviceda in Beginning Part 2 of Phase II/III trial for Geographic Atrophy

February is Age-Related Macular Degeneration (AMD) Awareness month, and DocTrials has been working on a lot.

DocTrials was mentioned on December 13th, 2023, when Ocugen dosed the first patient with OCU410, a potential treatment for dry AMD.

DocTrials worked with Orasis in their Phase III trial which was just FDA approved!